Viking Therapeutics Inc. became the fourth biopharma during first three days of the third quarter to indicate its intention to plumb the public markets with an initial public offering (IPO). San Diego-based Viking filed an S-1 with the SEC seeking to raise up to $57.5 million, including overallotments, for the offering, which is not yet priced.